



College on Problems of Drug Dependence

Conference | Washington DC Area | April 19-20, 2005

Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions

Chair: Edward M. Sellers, MD, PhD
 Professor, Pharmacology, Medicine and Psychiatry, University of Toronto
 President and CEO, Ventana Clinical Research Corporation

Co-Chair: Charles R. Schuster, PhD
 Professor of Psychiatry and Behavioural Neurosciences, Wayne State University

Tentative Conference Program

Introduction

Keynote Speaker

The program will consist of six to eight commissioned papers and presentations that will address various key relevant topics.

The meeting will address specific topics such as:

How formulation impacts on abuse liability	<input type="checkbox"/>	<input type="checkbox"/>	<i>In vitro</i> models
What is the public health risk, how is it measured?	<input type="checkbox"/>	<input type="checkbox"/>	Tampering and tamper resistance
New formulations as solutions to public health risk	<input type="checkbox"/>	<input type="checkbox"/>	New technology
Lessons from the past and present	<input type="checkbox"/>		Regulatory challenges
Case studies where formulation mattered	<input type="checkbox"/>		Research needs and proposals
Research methodology	<input type="checkbox"/>		

Discussion Group Workshops

Conference Summary and Research Recommendations

A number of positions on the program will be available for free oral communications from submitted abstracts.

Workshop Description:

The College on the Problems of Drug Dependence is pleased to provide a venue in which current opinion leaders from academia, government and industry can present on an array of topics that are currently impacting drug formulation. The emphasis will be on the formulation of centrally acting drugs (such as opiates and nicotine), the consequential potential for abuse and the resulting testing and regulatory processes that are necessary to ensure timely approval. The format of this conference has been designed to cover a wide range of topics from pre-clinical and clinical testing to issues of regulatory expectation and public health. The highlight of this conference will be the knowledge shared from leading experts in the field however it is also designed to generate discussion from all in attendance about how to move forward.

Conference Associate Sponsors:

To be announced

Who Should Attend?

The issues discussed at this conference will be of particular interest to three main stakeholders in drug formulation and approval: **the Pharmaceutical Industry (including Biotechnology firms and Contract Research Organizations), Government/Regulatory Agencies, and Academic Investigators**. Since the format will be partly an interactive workshop, it will appeal to individuals who wish to hear a wide range of experience and opinion.

Conference Objective:

The objective of this conference will be to review the history, current issues and research needs for the future of drug formulations so that new and current formulations are better able to positively reflect current abuse liability standards, safety concerns and regulatory decisions.